Intraoperative Monitoring of the Pelvic Autonomic Nerves

NCT ID: NCT01585727

Last Updated: 2019-02-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

188 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-06-30

Study Completion Date

2018-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

One of the major problems of rectal cancer surgery is pelvic autonomic nerve damage, which is the main cause of urogenital dysfunction influencing postoperative quality of life. Costs for diagnostics and treatment of short and long-term urogenital dysfunction are immense. Varying degrees of urogenital dysfunction are found in up to 32% and 55% of patients with rectal cancer despite potentially nerve-sparing total mesorectal excision (TME).

The study will examine the impact of a newly developed continuous monitoring device for preservation of urogenital function in patients with TME for rectal cancer. 188 patients will be included in the prospective, randomized, single-blind, parallel group multi-centre trial including two arms (TME with and without intraoperative continuous monitoring of pelvic autonomic nerves). The primary efficacy endpoint is the change in urinary function measured by International Prostate Function Score (IPSS) 12 months after surgery. Genital functions measured as secondary endpoints. The application of the continuous intraoperative neuromonitoring device could enhance the objective intraoperative confirmation of pelvic nerve sparing surgery. The investigators hypothesis is that the use of his device minimizes the risk of postoperative urogenital dysfunction in patients with TME for rectal cancer. An enormous reduction of treatment costs is to be expected.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rectal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TME with neuromonitoring

Total mesorectal excision with intraoperative neuromonitoring of pelvic autonomic nerves.

Group Type EXPERIMENTAL

TME

Intervention Type PROCEDURE

Total mesorectal excision

Neuromonitoring

Intervention Type PROCEDURE

Intraoperative neuromonitoring of pelvic autonomic nerves.

TME without neuromontoring

Total mesorectal excision without intraoperative neuromonitoring of pelvic autonomic nerves.

Group Type ACTIVE_COMPARATOR

TME

Intervention Type PROCEDURE

Total mesorectal excision

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TME

Total mesorectal excision

Intervention Type PROCEDURE

TME

Total mesorectal excision

Intervention Type PROCEDURE

Neuromonitoring

Intraoperative neuromonitoring of pelvic autonomic nerves.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* informed consent
* histologically confirmed carcinoma of the rectum (≤ 16 cm from anal verge)
* fit for radical surgery
* total mesorectal excision
* age 18-80 years

Exclusion Criteria

* history of operation of the urinary tract (e.g. prostatectomy)
* pacemaker
* emergency operation
* multivisceral resection in the pelvis
* partial mesorectal excision
* eligibility for local excision (TEM, intestinal wall resection)
* ongoing infection or sepsis
* severe untreated physical or mental impairment
* pregnancy or breastfeeding
* women of childbearing potential who are not using a highly effective birth control method
* missing preoperative data on urogenital or anorectal function
* simultaneous participation in another clinical trial
* previous participation in this clinical trial
* lack of cooperation with the trial procedure
Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Johannes Gutenberg University Mainz

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Werner Kneist

Senior physician, Department of Visceral and Abdominal Surgery

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Werner Kneist, Univ.-Prof.

Role: PRINCIPAL_INVESTIGATOR

Department of Visceral and Abdominal Surgery, University Medical Center Mainz

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of General and Visceral Surgery, University Medical Center Mainz

Mainz, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

References

Explore related publications, articles, or registry entries linked to this study.

Kauff DW, Kronfeld K, Gorbulev S, Wachtlin D, Lang H, Kneist W. Continuous intraoperative monitoring of pelvic autonomic nerves during TME to prevent urogenital and anorectal dysfunction in rectal cancer patients (NEUROS): a randomized controlled trial. BMC Cancer. 2016 May 21;16:323. doi: 10.1186/s12885-016-2348-4.

Reference Type DERIVED
PMID: 27209237 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2007-012

Identifier Type: -

Identifier Source: org_study_id

KN 930/1-1

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.